Avaliação do Melanoma Inhibitory Activity - MIA em pacientes com Melanoma Cutâneo no Estado de Mato Grosso do Sul

Abstract

The incidence of cutaneous melanoma (CM) has increased in recent years. Metastasis is part of the staging of the CM and is related to the prognosis. The main application of tumor markers in monitoring response to therapy and early detection of recurrent disease in follow-up of CM patients. Melanoma Inhibitory Activity (MIA) has been shown to be a good tumor marker for CM. There is no Brazilian study about MIA and CM. Therefore, the objective of this study is to evaluate the blood test MIA in patients with CM of Mato Grosso do Sul, Brazil. To accomplish the objective, patients diagnosed with CM in the Laboratory of Pathology, LAC, Campo Grande - MS, from April 2008 to October 2009 were invited to participate in the study. Oncologists from this city were contacted and informed to invite their patients with CM to participate in the study. The measurement of serum MIA was made by the MIA-ELISA test (Roche ®). Each patient had 1 sample collected. As results, in total, blood samples from 15 CM patients without metastasis (Group 1) and 10 patients with metastasized CM (Group 2) were collected. For comparison, blood samples from 5 healthy persons (control group) were collected. Group 1 was consisted of 8 women and 7 men, Group 2 by 2 women and 8 men, and the control group by 3 women and 2 men. The average age of Group 1 was 60.3 years (28 to 80 years), of Group 2 was 60.8 years (39 to 59 years). Serum levels of MIA in Group 1 ranged from 3.5 ng / ml to 11.1 ng / ml, with an average of 6.78 ng / ml; Group 2 ranged from 5.8 ng / ml to 30.0 ng / ml with an average of 21.21 ng / ml. Serum levels of the control group ranged from 4.0 ng / ml to 8.6 ng / ml, with an average of 5.64 ng / ml. There was statistical difference between serum levels of the Groups with and without metastasis (Groups 1 and 2) and between the group with metastasis (Group 2) and the control group. There was no difference between the groups without metastasis and control group. Therefore, we concluded that serum levels of MIA in patients without metastasis and / or clinical relapse were significantly lower than those of patients with metastasis and / or clinical relapse. There was no statistically significant difference between serum levels of MIA without metastasis and control group. MIA test is easy, cost-feasible, and could be used in the follow-up of patients treated of CM.